In preclinical mouse tumor models, TGFβ inhibition with immune checkpoint blockade induces complete and durable responses in otherwise unresponsive tumors (Mariathasan et al., 2018; Tauriello et al., 2018). The gene discussed is TGFB1; the disease is neoplasm.